Headlands Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Headlands Technologies’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.58M	Buy	+10,545	New	+$7.18M	0.7%	23
2025 Q4	–	Sell	-4,014	Closed	-$2.26M	–	838
2025 Q3	$2.26M	Sell	4,014 -8,639	-68%	-$4.88M	0.18%	126
2025 Q2	$6.64M	Buy	12,653 +9,259	+273%	+$5.17M	0.8%	21
2025 Q1	$2.15M	Sell	3,394 -1,997	-37%	-$1.37M	0.25%	104
2024 Q4	$3.84M	Sell	5,391 -201	-4%	-$169K	0.39%	58
2024 Q3	$5.88M	Buy	+5,592	New	+$6.22M	0.68%	28
2024 Q2	–	Sell	-845	Closed	-$813K	–	1531
2024 Q1	$813K	Sell	845 -398	-32%	-$378K	0.2%	130
2023 Q4	$1.09M	Buy	1,243 +1,238	+24,760%	+$1.02M	0.33%	71
2023 Q3	$4.12K	Buy	+5	New	+$3.93K	﹤0.01%	778
2023 Q1	–	Sell	-3,235	Closed	-$2.33M	–	716
2022 Q4	$2.33M	Buy	+3,235	New	+$2.39M	1.85%	9

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Headlands Technologies's REGN Position: Q2 2026 in Review

Headlands Technologies opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 10,545 shares worth $6.58M. The stake represents 0.7% of the portfolio and ranks #23 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in REGN as recently as Q3 2025.

Headlands Technologies first reported a position in REGN in Q4 2022 and has held it in 10 quarters since. The position peaked at $6.64M in Q2 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Headlands Technologies held 10,545 shares of Regeneron Pharmaceuticals worth $6.58M as of Q2 2026.
Regeneron Pharmaceuticals was a new Headlands Technologies position in Q2 2026.
Regeneron Pharmaceuticals made up 0.7% of Headlands Technologies's portfolio in Q2 2026, its #23 holding.
Headlands Technologies first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
Headlands Technologies's Regeneron Pharmaceuticals position peaked at $6.64M in Q2 2025.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.